ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CLLS / dividends
NKTX (31) NRXP (36) TLSA (55) ANIX (32) ⌘ Pro Terminal →

Cellectis S.A. (CLLS) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.08 -7.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.06

Cellectis S.A. (CLLS) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $117.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLLS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Cellectis S.A. (NASDAQ: CLLS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.08 (-7.69% 1D, market cap $117.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CLLS ranks #314 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLLS compare to NKTX and NRXP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLLS carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NKTX (Nkarta Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $118.9M) and NRXP (NRX Pharmaceuticals Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $115.2M). Among the 5-stock peer group, CLLS leads on earnings multiple (N/A) while NKTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLLS?
▼

For Cellectis S.A. (CLLS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #314 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.06 (-1.57%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510049
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (5)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.7% Base Target
$6 Bull$1 Base$1 Bear
📬 FREE CLLS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLLS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY CLLS SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($3.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
57
Grade C$1.26-17.5% Next Q
Q2 (-2Q)
54
Grade C-$1.04-5.8% Next Q
Q3 (-1Q)
52
Grade C-$0.98+10.2% Next Q
Current
49
Grade D$1.08-5.4% Hist 90D α
Trajectory: C (57) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLLS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLLS currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.89) and Max Pain ($1.13) forces dealer call-delta covering toward $5.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLLS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLLS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 49%NO 51%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLLS)

  • ✓Walkthrough of CLLS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CLLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -72.31%▼ DESCENDING CHANNEL
2026-10-30O $1.15H $1.15L $1.07C $1.08VOL 12.3K
RES: $3.23SUP: $0.48SMA50: $1.89SMA200: $3.07
$4.42$3.46$2.50$1.54$0.58RES $3.23SUP $0.48$1.082026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLLS Butterfly Map → + Track CLLS →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLLS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLLS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLLS)

Health Care Rank #314 of 1016 ⚔️ NKTX vs CLLS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLLS vs. NKTX, NRXP, TLSA, ANIX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cellectis S.A. (CLLS) ranks #314 by composite RQD confidence (49/100, grade D) and #638 by equity capitalization ($117.6M). Within this direct 5-issuer industry benchmark cohort, CLLS leads on earnings valuation at N/A trailing P/E, while NKTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TLSA currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with CLLS at 49/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLLS ACTIVE
Cellectis S.A.
D 49/100 — — — -7.69% $117.6M Benchmark Subject
NKTX
Nkarta Inc.
E 31/100 — — -35.0% -6.02% $118.9M /nktx-vs-clls →
NRXP
NRX Pharmaceuticals Inc.
D- 36/100 — 58.8% -35.0% -14.66% $115.2M /nrxp-vs-clls →
TLSA
Tiziana Life Sciences Ltd.
D+ 55/100 — — — -11.57% $115.1M /tlsa-vs-clls →
ANIX
Anixa Biosciences Inc.
E 32/100 — — -35.0% -5.45% $114.7M /anix-vs-clls →

2. CLLS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Cellectis S.A. (CLLS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $117.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. CLLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Cellectis S.A. (NASDAQ: CLLS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $1.08 (-7.69% 1D, market cap $117.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CLLS ranks #314 in composite RQD confidence.

How does CLLS compare to NKTX and NRXP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLLS carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NKTX (Nkarta Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $118.9M) and NRXP (NRX Pharmaceuticals Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $115.2M). Among the 5-stock peer group, CLLS leads on earnings multiple (N/A) while NKTX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLLS?

For Cellectis S.A. (CLLS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #314 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLLS trading relative to its 50-day, 200-day, and 52-week technical levels?

CLLS last traded at $1.08 (-7.69% on volume of 12,274 shares), positioning the stock -42.86% below its 50-day simple moving average ($1.89) and -64.82% below its 200-day simple moving average ($3.07). Across its 52-week range of $0.88 to $5.45, CLLS sits at the 4.4% percentile with a 14-day RSI of 37.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.22).

CLLS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does CLLS pay a dividend and is it safe?

Cellectis S.A. (CLLS) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: CLLS RQD Cockpit CLLS 12M Forecast CLLS Earnings & Move CLLS Dividends & DRIP CLLS Insiders & 13F CLLS Whale Options CLLS Profit Sankey CLLS News & Why
ROARABLE RATING BRIEF • RQD 49/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CLLS — Cellectis S.A.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:18:15Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CLLS scores 49 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The score is the sum of five pillars, each weighted out of 20. The Fundamental Cash Engine pillar scores 12/20, reflecting an ROIC of 0% and an FCF yield of 0%; for a prospective investor, this means the rating finds no current cash generation to anchor valuation. The Whale 13F Flow pillar scores 5/20 on institutional accumulation and options positioning, the weakest pillar and a signal of limited institutional support. The Insider Conviction pillar scores 9/20 on SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 10/20, with a Beta of 1.0 and a sector sensitivity that the rating does not further specify. The Forensic Balance Sheet pillar scores 13/20, the strongest pillar, with an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5. Taken together, the upside case rests on balance-sheet resilience and the stock's low absolute price, while the valuation tradeoff is that the rating identifies no earnings or cash flow base against which the price can be measured. The distribution warning in the verdict label signals that the rating's framework views the current setup as unfavorable for holding.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most recent items (all tagged YELLOW, MARKET WIRE) are:

  • Yahoo! Finance Canada stock-price and quote coverage (1h ago).
  • MarketBeat coverage of a consensus target price of $5.46 among analysts (3h ago).
  • Stock Titan coverage stating that one dose lowered blood fats by 75% on average in mice and that Cellectis plans a China trial (6h ago).
  • GlobeNewswire coverage of a securities fraud investigation into Cellectis S.A. (9h ago).
  • Kalkine Media coverage of the company's APOC editing candidate (12h ago).
  • MarketBeat coverage of the Q3 2026 earnings date and estimates (15h ago).

Key risk watch items: the securities fraud investigation headline is the most material risk flag in the feed, and it is unresolved in the source data. The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals, so no graph-derived catalyst exists.

Open Questions

  • What is the scope and status of the securities fraud investigation referenced in the GlobeNewswire item, and does it bear on the company's reported figures?
  • What are the company's reported revenue, operating income, net income, and cash flow for recent periods, given that the financials section is empty?
  • What is the company's current product pipeline and commercial revenue base, beyond the mouse-study and APOC candidate references in the news feed?
  • What is the basis for the $5.46 consensus target price, and how does it compare with the $1.08 current price and the $0.88–$5.45 52-week range?
  • What are the cash runway and debt maturity schedule underlying the Debt/Equity of 0.5 and the Altman Z of 2.5?

CLLS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cellectis S.A. (CLLS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLLS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLLS Bull vs. Bear Conversation Board — What's Your Call at $1.08?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLLS 🐻 50% BEARISH CONVICTION
1. Pick Your Side on CLLS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.17 (+8.3%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CLLS (D • RQD 49/100) a Buy at $1.08?

Welcome to the CLLS (Cellectis S.A.) Roar Pit. Current RQD Composite is 49/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.85 (-21.3%)
Spot @ $1.08

Pump the brakes on CLLS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CLLS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cellectis S.A. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.23 (+13.9%)
Spot @ $1.08

CLLS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CLLS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.08 (52-wk range $0.88 - $5.45), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%